1. 1

From the publication:

The best current evidence suggests that short-term, high-dose testosterone administration mildly worsens OSA [obstructive sleep apnea]. Longer-term TTh [testosterone therapy] in subjects undergoing concomitant weight loss was shown to mildly worsen OSA but only initially. By 18 weeks, patients demonstrated return to baseline levels of OSA risk. These results suggest that TTh’s role in exacerbating OSA is small and may be time limited. However, it is also possible that weight loss acted as a confounding factor. Additional studies are needed to determine if men who are more obese at baseline have a higher risk of developing OSA with TTh than nonobese men. Why testosterone would have a timedependent effect, however, remains unanswered. Regarding the mechanisms by which TTh may worsen OSA, anatomic TTh-induced airway changes and altered sleep stage architecture have been largely refuted. The mechanism of action is more likely related to altered hypoxic and hypercapnic ventilatory response with testosterone administration, though work is still needed to resolve inconsistencies in currently available studies. Until these questions are more fully understood, clinicians may choose to exercise caution in prescribing TTh to individuals with severe, untreated OSA.

  1. You must first login , or register before you can comment.

    Markdown formatting available